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ABSTRACT 
Objective 
The CHN2 gene encodes the β2-chimaerin, a Rac specific GTPase activating 
protein with an important role in the establishment of functional brain circuitry by 
controlling axon pruning. Genetic studies suggest that the CHN2 gene harbors variants 
that contribute to addiction vulnerability and smoking behavior. To further evaluate the 
role of β2-chimaerin in nicotine addiction, we investigated the association of three 
individual polymorphisms of the CHN2 gene with smoking dependence. 
Methods 
361 healthy volunteers, 173 smokers (mean age 60.4 ±1.4) and 188 control 
subjects (mean age 45.9 ±1.4) were genotyped for three single nucleotide 
polymorphisms
 
in the CHN2 gene (rs3750103, rs12112301 and rs186911567). The 
association of these polymorphisms with smoking habits was analyzed. 
Results 
There was no significant association of polymorphisms rs12112301 and 
rs3750103 with smoking. However, there was a significant difference in the frequency 
of the rs186911567 polymorphism between smokers and controls (p = 0.003).  
Conclusions 
We report for the first time a significant association of the novel rs186911567 
polymorphism of the CHN2 gene with smoking.  
 
Keywords:  2-chimaerin, CHN2, addiction, polymorphisms, smoking. 
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INTRODUCTION 
Tobacco addiction is a complex brain disorder that involves multiple molecular 
components and has a strong genetic influence [1]. Numerous factors contribute to the 
long lasting nature of tobacco addiction, such as the structural changes induced by 
nicotine in neurons and its effect on synaptic plasticity [2]. Actin cytoskeleton drives 
the neuroadaptations produced by nicotine, and therefore, several genes encoding 
proteins involved in cytoskeleton regulation harbor allelic variants that contribute to 
smoking dependence [3]. Among these, the CHN2 gene has been identified in genome-
wide association studies (GWAS) of nicotine dependence as a candidate for harboring 
variants involved in smoking addiction [4]. The human CHN2 gene maps to 
chromosome 7p15.3, has 13 exons and encodes the β2-chimaerin, a GTPase activating 
protein (GAP) highly expressed in the brain [5]. β2-chimaerin selectively inactivates Rac, 
a small GTPase with a prominent role in the control of actin cytoskeleton dynamics [6, 
7]. Recent work in animal models has demonstrated the essential role of β2-chimaerin in 
controlling axon pruning in the hippocampus [8]. In humans, the missense 
polymorphism (H204R) on the CHN2 gene is associated with schizophrenia [9], a 
disorder with high rate of comorbidity with smoking [10]. Considering the evidences for 
the involvement of the CHN2 gene in tobacco addiction, we focused this study on 
identifying the association of individual SNPs on the CHN2 gene with smoking. We 
analyzed three polymorphisms of potential relevance for β2-chimaerin function: 
polymorphism rs3750103 c.611A>G (p.H204R) in exon 7 previously associated with 
schizophrenia, polymorphism rs12112301 (IVS5+7C>T) located on intron 5 that could 
influence on splicing, and polymorphism rs186911567 c.366G>A (p.S122S) in exon 6, 
a novel synonymous polymorphism recently identified in our laboratory.  
5 
 
 
MATERIALS AND METHODS 
Subjects 
The three SNPs were genotyped in 361 Caucasians from Castilla y León, Spain. 
173 participants were current smokers (mean age 60.4 ±1.4 years, 74.0 % males) which 
fulfilled the DMS-IV criteria for nicotine dependence dictated by the American 
Psychiatric Association, and were referred to the Tobacco Addiction Unit of the 
University Hospital of Salamanca, Spain.   The control group consisted of 188 subjects 
(mean age 45.9 ± 1.4 years, 75.0% males) which had a lifetime history of no more than 
100 cigarettes without developing an addiction to tobacco. Neither smokers nor controls 
had any mental disorder, or personal or familiar history of lung cancer. All subjects 
gave informed consent to participate, and the study was approved by institutional ethical 
committees.  
Genotyping 
Genotypes of the rs12112301 and rs3750103 polymorphisms were determined 
using the TaqMan 5´-exonuclease allelic distribution assay (Applied Biosystems, Foster 
City, USA).  The rs186911567 polymorphism was studied by PCR-restriction fragment 
length polymorphism-based analysis and digestion with TaqI. Primers used for the 
amplification were forward: 5’-TATCATTCCACACTGTGCTTAT-3’, and reverse: 5’-
TCAGCAAATCGCACCTATAGT-3’. The amplified 433 bp fragment was digested 
overnight at 65 °C with TaqI and the resulting fragments (298 bp and 135 bp for A 
allele and 433 bp for G allele) were separated on a 3% agarose gel. 
Statistical analysis 
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Hardy–Weinberg equilibrium was determined with the χ2 test. Genotype 
frequencies of smokers and controls, and smokers´ subgroups, were compared by means 
of χ2 test and Fisher’s exact test when necessary (expected values below 5). P < 0.05 
was considered as significant for the differences between the genotypes. All statistical 
analyses were performed using the statistical software SPSS v.19.0 (SPSS Inc., 
Chicago, IL).  
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RESULTS 
Table 1 shows genotype distributions of the three polymorphisms of the CHN2 
gene among the smokers and controls. Frequencies of the rs12112301 and rs3750103 
polymorphisms were in Hardy-Weinberg equilibrium in the control group and no 
significant differences were observed among smokers and controls. However, we found 
a significant difference in the frequency of the rs186911567 polymorphism between 
smokers and controls.  4.6% of smokers had the GA or AA genotypes while no carriers 
of the A allele were found in the control group (p = 0.003). Hardy-Weinberg 
equilibrium was not considered for this polymorphism in the control group since only 
carriers of the GG genotype were found in these subjects. 
To determine the factors contributing to the association of the rs186911567 
polymorphism with smoking, we next analyzed this polymorphism in smokers grouped 
according to their age and smoking habits (Table 2). There was no significant 
association of this polymorphism with the daily cigarette consumption (up to or more 
than 20), years of smoking (up to or more than 30) or age (>65 vs. <65).   However, 
there was a trend towards an increased frequency of the polymorphism in older smokers 
(p = 0.07). 7.5% of smokers older than 65 had the GA or AA genotypes, while only 
1.25% of smokers younger than 65 had the GA genotype and no carriers of the AA 
genotype were found in this group. These data suggest that the rs186911567 
polymorphism does not influence smoking quantity (estimated by the number of 
cigarettes smoked per day) but may influence duration of smoking.  
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DISCUSSION 
In this study we evaluate for the first time the association of individual SNPs of 
the CHN2 gene with smoking. Our results are in agreement with the suggested role for 
the CHN2 gene in addiction. Uhl et al. [4] identified the CHN2 among the genes that 
facilitate nicotine abstinence in smokers treated with nicotine replacement therapies or 
bupropion. Our study, however, identify a SNP that contributes to smoking. Thus, our 
data are consistent with whole genome association studies that identify the CHN2 gene 
among the 89 genes with variants that contribute to addiction vulnerability [11]. 
The functional relevance of the synonymous rs186911567 polymorphism is 
currently unknown. Although the G →A substitution at position 366 in exon 6 does not 
result in aminoacid change, bioinformatics analysis predicts the disruption of exonic 
splicing enhancer motifs and loss of a binding site for the splicing factor SC35 (Human 
Splicing Finder) [12]. Therefore, a theoretical option is that polymorphism rs186911567 
could alter the splicing of the 2-chimaerin transcript, rendering an inactive protein by 
skipping of exon 6 and generation of a premature stop codon. Inactivation of 2-
chimaerin would result in increased Rac activity and altered actin cytoskeleton 
remodeling, an important process for the nicotine effect on neural plasticity. 
Interestingly, chn2 knockout mice show defects in axon and synaptic pruning, processes 
that are unbalanced in numerous mental disorders [13]. Furthermore, polymorphisms in 
the NRXN3 gene, important regulator of dendritic and axonal arbors remodeling, have 
been associated with smoking as well as with schizophrenia [14, 15]. 
Other pathways may also contribute to the role of 2-chimaerin on nicotine 
dependence. Recent data demonstrate that the effects of nicotine on learning and 
memory are in part mediated by JNK signaling in the hippocampus, which may explain 
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the long-lasting modifications of behavior induced by nicotine that contributes to 
addiction [16]. It is plausible that 2-chimaerin regulates JNK activity in hippocampal 
neurons since it has been reported the expression of this protein in the hippocampus [8] 
and the role of 2-chimaerin in the regulation of JNK has been already demonstrated in 
epithelial cells [17]. 
In summary, our study is the first report of a novel SNP polymorphism of the 
CHN2 gene that may contribute to smoking behavior. Because of the relatively small 
sample size, this is a preliminary study. However, our results are in line with a role of 
the CHN2 gene in smoking and support the relevance of this protein in addiction. Based 
on these findings and the known biological role of 2-chimaerin, further studies are 
needed to corroborate the utility of rs186911567 polymorphism as a genetic marker for 
smoking dependence. 
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  rs12112301 (IVS5+7C>T) 
  Genotype  Grouped Genotypes  HWE controls 
 N  CC CT TT  CC CT/TT Χ2 df p Χ2 p 
Control subjects 188  151 (0.803) 34 (0.181) 3(0.016)  0.803 0.197 
0.071 1.000 0.790 0.448 0.503 
Smokers 173  137 (0.792) 36 (0.208) 0 (0.000)  0.792 0.208 
  rs186911567  c.366G>A (p.S122S) 
   Genotype  Grouped Genotypes   
 N  GG GA AA  GG GA/AA   p   
Control subjects 188  188 (1.000) 0 (0.000) 0 (0.000)  1.000 0.000 
  0.003
a
   
Smokers 173  165 (0.954) 7 (0.040) 1 (0.006)  0.954 0.046 
  rs3750103 c.611A>G (p.H203R) 
   Genotype  Grouped Genotypes  HWE controls 
 N 
 
His/His His/Arg Arg/Arg 
 
His 
His/Arg and 
Arg/Arg 
Χ2 df p Χ2 p 
Control subjects 188  164 (0.872) 24 (0.128) 0 (0.000)  0.872 0.128 
0.489 1.000 0.485 0.874 0.350 
Smokers 173  155 (0.896) 18 (0.104) 0 (0.000)  0.896 0.104 
Table 1 Genotype frequencies of the CHN2 polymorphisms, rs12112301 (IVS5+7C>T), rs3750103 c.611A>G (p.H203R) and rs186911567 c.366G>A (p.S122S) 
in smokers and control subjects 
 
 
 
aFisher’s exact test 
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 Genotype  Grouped Genotypes  
 N GG GA AA  GG GA/AA p 
Age (years)         
<65 80 79 (0.988) 1 (0.012) 0 (0.000)  0.988 0.012 
0.070
a
 
>65 93 86 (0.925) 6 (0.065) 1 (0.011)  0.925 0.075 
Cigarettes/day         
Up to 20 97 91 (0.938) 5 (0.052) 1 (0.010)  0.928 0.062 
0.468
a
 
More than 20 76 74 (0.974) 2 (0.026) 0 (0.000)  0.974 0.026 
Years smoking         
Up to 30 78 76 (0.974) 2 (0.026) 0 (0.000)  0.974 0.026 
0.297
a
 
More than 30 95 89 (0.937) 5 (0.053) 1 (0.011)  0.937 0.046 
Table 2 Genotype frequencies of the CHN2 rs186911567 c.366G>A (p.S122S) polymorphism in smokers with different age 
and smoking behavior  
aFisher’s exact test 
